SecBot SecBot
8-K ·Filed Nov 5, 2026

XERS

Xeris Biopharma Holdings, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed11d 20h ago SEC0001867096-26-000114
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The raised 2026 guidance and significantly increased 2030 revenue outlook signal accelerating commercial momentum, particularly from Recorlev. Monitor the XP-8121 Phase 3 Cornerstone study initiation by year-end 2026 and topline data expected in late 2028.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$13.08
T+0 close · Nov 5, 2026 · via day close
Latest settled
+27.29%
T+5 · $16.65
Vs SPY
+24.00%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $13.08entry
  2. T+1 · 11d ago +16.21%α +15.90% · $15.20
  3. T+5 · 5d ago +27.29%α +24.00% · $16.65
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Xeris reported Q3 2026 total revenue of $107.2M, up 44% YoY and above the $101.7M consensus, driven by Recorlev net revenue of $71.5M (+93% YoY). GAAP net income was $11.3M vs $0.6M a year ago. The company raised full-year 2026 revenue guidance to $395M-$405M and raised its 2030 revenue outlook to over $1B, up from approximately $750M.

Key Financial Metrics

EPS
$0.06
est $0.03 · +100.0%
Revenue
$107.2M
est $101.7M · +5.4% · +44.1% YoY
Rating
strong beat
Guidance
$395M-$405M
raised
Gross Margin
88%

Key Facts

  • Total revenue $107.2M, up 44% YoY, above consensus of $101.7M
  • Recorlev net revenue $71.5M, up 93% YoY
  • GAAP net income $11.3M vs $0.6M YoY
  • Adjusted EBITDA $30.8M vs $17.4M YoY
  • Full-year 2026 revenue guidance raised to $395M-$405M
  • 2030 revenue outlook raised to over $1B from approximately $750M
  • Gross margin improved to 88% from 85% YoY
  • 2028 Convertible Notes fully retired, eliminating ~$34M debt and ~$3M annual interest expense

Financial Impact

Revenue beat of ~$5.5M vs consensus; guidance raised by $10M at midpoint; 2030 outlook increased by >$250M

revenuenet incomeadjusted EBITDAguidance

Segment Breakdown

SegmentRevenueGrowth
Recorlev$71.5M+93.0%
Gvoke$21.7M-14.0%
Keveyis$13.0M+9.0%

Risk Factors

  • Gvoke revenue declined 14% YoY with a one-time $4M gross-to-net adjustment
  • SG&A expenses increased 38% YoY, outpacing revenue growth
  • XP-8121 remains in development with no near-term revenue contribution

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001867096-26-000114
Document: xers-20261105.htm0001867096-26-000114
Document: 0001867096-26-000114-index-headers.html0001867096-26-000114
Document: 0001867096-26-000114-index.html0001867096-26-000114
Document: 0001867096-26-000114.txt0001867096-26-000114
8-K Data (Synthetic)0001867096-26-000114

Track record

25 reports on XERS

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +45.52% at T+60 after the Aug 6, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $15.86 Now $16.70 +5.30% settles Dec 8
  2. Nov 5, 202611d ago 144 Neutral 2/10 Entry $15.20 Now $16.70 +9.87% settles Dec 7
  3. Nov 5, 202611d ago 8-K Bullish 6/10 Viewing Entry $13.08 Now $16.70 +27.68% settles Dec 4
  4. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
  5. Nov 4, 202612d ago 3 Neutral 2/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
  6. Nov 2, 202614d ago 144 Neutral 2/10 Entry $10.35 Now $16.70 +61.35% settles Dec 2
  7. Nov 2, 202614d ago 8-K Neutral 2/10 Entry $10.17 Now $16.70 +64.21% settles Dec 1
  8. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $10.71 Now $16.70 +55.93% settles Nov 30
  9. Oct 14, 20264w ago 8-K Neutral 3/10 Entry $9.77 to $16.52 Now $16.70 +70.93% ▲ +69.09% +70.36% vs SPY
  10. Oct 2, 20266w ago Insider Cluster Neutral 3/10 Entry $10.13 to $10.71 Now $16.70 +64.86% ▲ +5.73% +8.19% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 5h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026